These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37827871)

  • 21. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
    Garstka M; Henriquez A; Kelly BN; Webster A; Khubchandani JA; Hughes K; Nguyen A; Oseni T; Specht M; Coopey SB; Gadd MA; Smith BL
    Ann Surg Oncol; 2021 Oct; 28(10):5657-5662. PubMed ID: 34296361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
    Comeaux JG; Culver JO; Lee JE; Dondanville D; McArthur HL; Quinn E; Gorman N; Ricker C; Li M; Lerman C
    Mol Genet Genomic Med; 2022 Oct; 10(10):e2031. PubMed ID: 36054727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
    Semple J; Metcalfe KA; Lynch HT; Kim-Sing C; Senter L; Pal T; Ainsworth P; Lubinski J; Tung N; Eng C; Gilchrist D; Blum J; Neuhausen SL; Singer CF; Ghadirian P; Sun P; Narod SA;
    Ann Surg Oncol; 2013 Nov; 20(12):3817-22. PubMed ID: 23740344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
    Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
    Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
    Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Counselling Framework for Germline
    Wong SM; Apostolova C; Eisenberg E; Foulkes WD
    Curr Oncol; 2024 Jan; 31(1):350-365. PubMed ID: 38248108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes.
    Ntowe KW; Thomas SM; Dalton JC; Olunuga E; Wang T; Chiba A; Plichta JK
    Ann Surg Oncol; 2024 Oct; 31(11):7290-7300. PubMed ID: 38976158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
    Madorsky-Feldman D; Sklair-Levy M; Perri T; Laitman Y; Paluch-Shimon S; Schmutzler R; Rhiem K; Lester J; Karlan BY; Singer CF; Van Maerken T; Claes K; Brunet J; Izquierdo A; Teulé A; Lee JW; Kim SW; Arun B; Jakubowska A; Lubinski J; Tucker K; Poplawski NK; Varesco L; Bonelli LA; Buys SS; Mitchell G; Tischkowitz M; Gerdes AM; Seynaeve C; Robson M; Kwong A; Tung N; Tessa N; Domchek SM; Godwin AK; Rantala J; Arver B; Friedman E
    Breast Cancer Res Treat; 2016 Jun; 157(2):319-327. PubMed ID: 27117159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
    Heemskerk-Gerritsen BA; Menke-Pluijmers MB; Jager A; Tilanus-Linthorst MM; Koppert LB; Obdeijn IM; van Deurzen CH; Collée JM; Seynaeve C; Hooning MJ
    Ann Oncol; 2013 Aug; 24(8):2029-35. PubMed ID: 23576707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
    Stanek K; Zimovjanova M; Suk P; Jonas F; Zimovjanova A; Molitor M; Mestak O
    Aesthetic Plast Surg; 2022 Apr; 46(2):706-711. PubMed ID: 34342702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-reducing mastectomy for BRCA gene mutation carriers.
    Euhus DM
    Ann Surg Oncol; 2015 Sep; 22(9):2807-9. PubMed ID: 25821000
    [No Abstract]   [Full Text] [Related]  

  • 36. Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
    Galmor L; Bernstein-Molho R; Sklair-Levy M; Madoursky-Feldman D; Zippel D; Laitman Y; Friedman E
    Breast Cancer Res Treat; 2021 Jan; 185(2):391-399. PubMed ID: 33000375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
    O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
    Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
    Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
    J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery.
    Shapira R; Turbitt E; Erby LH; Biesecker BB; Klein WMP; Hooker GW
    Fam Cancer; 2018 Oct; 17(4):485-493. PubMed ID: 29209897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.